NEXT GENERATION PEPTIDE DRUGS FAVOR SYNTHETIC, NOT RECOMBINANT MANUFACTURING
The advent of new drugs targeting diabetes, obesity, and cardiovascular diseases has sparked a surge in the demand for polypeptide manufacturing. This surge, in turn, has propelled an industrial intensification…
Report on Results from ICMRA-WHO Workshop Addressing Strain Changes in COVID-19 Vaccines
Today, the joint effort of the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO) culminated in the publication of a comprehensive report detailing the outcomes…
FINTLEPLA®▼ (fenfluramine) oral solution gains approval in Japan as adjunctive therapy for seizures linked with Lennox-Gastaut syndrome (LGS)
UCB’s FINTEPLA®▼ (fenfluramine) oral solution has received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating seizures linked with Lennox-Gastaut syndrome (LGS) as an additional therapy…
Merck Sparks Curiosity: 2024 STEM Careers Exploration Tour with the Curiosity Cube
Merck’s Curiosity Cube Hits the Road: Inspiring 45,000 Students Across 14 Countries Merck, a global leader in science and technology, has launched its 2024 Curiosity Cube tour from Darmstadt, Germany,…
Jumar Bioincubator Launches Mission: Crafting Australia’s Future CSL with Mini-Brains and Lab-on-a-Chip Wearables
Australia’s Latest Biotech Incubator, Jumar Bioincubator, Unveils First Cohort of Innovative Ventures Melbourne, Australia – Jumar Bioincubator, the newest addition to Australia’s biotech landscape, has officially opened its doors, showcasing…
48-Week Phase 2 Frexalimab Data Shows Promising, Sustained Efficacy in MS
Sanofi’s frexalimab, a CD40L antibody, has displayed enduring effectiveness and favorable tolerability over almost a year in individuals with relapsing multiple sclerosis (MS). These findings will be unveiled today at…
Six-Year Efficacy of Novartis Kesimpta® in Newly Diagnosed Relapsing MS Patients
Novartis has unveiled findings from the ALITHIOS open-label extension study, spotlighting the enduring effectiveness of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing…
AstraZeneca Pioneers Advances in Infectious Disease Protection at ECCMID 2024
AstraZeneca is gearing up to present a wealth of new clinical, real-world, and early science data encompassing its Vaccines & Immune Therapies portfolio at the 34th European Congress of Clinical…
Alert: Falsified (Contaminated) USP/EP Propylene Glycol – Medical Product Alert N°1/2024
Alert Overview This alert from the World Health Organization (WHO) addresses the discovery of falsified DOW USP/EP Propylene Glycol in Pakistan. Authentic DOW USP/EP Propylene Glycol is a crucial raw…
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Viatris, a leading global healthcare company, has announced the appointment of Corinne Le Goff as its Chief Commercial Officer, effective immediately. Le Goff brings over 25 years of experience in…
WuXi Biologics Chosen for S&P Global Sustainability Yearbook 2024
WuXi Biologics, known as WuXi Bio (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces its selection for the prestigious S&P Global Sustainability Yearbook 2024 (“Yearbook”)…
Labcorp Unveils Groundbreaking Blood Test for Early Detection of Neurodegenerative Diseases and Brain Injuries
Labcorp, a leading provider of innovative laboratory services globally, has announced the launch of the nation’s inaugural glial fibrillary acidic protein (GFAP) test. This test serves as a pivotal blood-based…